logo.png
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
June 07, 2021 08:45 ET | Adhera Therapeutics, Inc.
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
logo.png
Adhera Therapeutics Appoints Trond K. Waerness to Board of Directors
April 23, 2021 09:00 ET | Adhera Therapeutics, Inc.
Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the...
logo.png
Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock
September 26, 2019 16:19 ET | Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
logo.png
Adhera Therapeutics Announces Termination of Tender Offer for Warrants
July 02, 2019 16:15 ET | Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
logo.png
Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer
April 04, 2019 09:15 ET | Adhera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, NC, April 04, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and...
logo.png
Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update
November 20, 2018 19:08 ET | Adhera Therapeutics, Inc.
Research Triangle Park, NC, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
October 09, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Nancy R. Phelan to the Board of Directors
October 03, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Eric Teague as Chief Financial Officer
September 24, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations
August 06, 2018 09:15 ET | Marina Biotech, Inc.
City of Industry, CA, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...